错配无关供者外周血干细胞移植后基于移植后环磷酰胺的移植物抗宿主病预防
这项II期非随机多中心试验评估了145例接受HLA错配无关供者外周血干细胞移植的成人患者,采用环磷酰胺、他克莫司和吗替麦考酚酯预防GVHD。清髓预处理组1年总生存率为83.8%,减低强度/非清髓预处理组为78.6%,急性III-IV级GVHD和慢性GVHD发生率较低。
要点
- 清髓预处理组1年总生存率为83.8%(95%CI 73.1-90.4),减低强度/非清髓组为78.6%(95%CI 67-86.5)。
- 6个月急性III-IV级GVHD发生率:清髓组8%,减低强度/非清髓组10%。
- 1年中/重度慢性GVHD发生率:清髓组10.3%,减低强度/非清髓组8.6%。
核心结论
- 基于移植后环磷酰胺的GVHD预防方案在错配无关供者外周血干细胞移植后获得良好的1年总生存率。
- 使用错配无关供者可扩大供者来源,使所有患者无论血统均可获得移植。
研究设计与样本
- II期、非随机、多中心试验,评估环磷酰胺、他克莫司和吗替麦考酚酯的GVHD预防方案。
- 研究纳入145例成人患者,分为清髓预处理(MAC)和减低强度/非清髓预处理(RIC/NMA)两个分层。
- 主要目标为估计各分层1年总生存率,关键次要终点包括急性和慢性GVHD发生率。
主要发现
- 1年总生存率:MAC组83.8%(95%CI 73.1%-90.4%),RIC/NMA组78.6%(95%CI 67%-86.5%)。
- 6个月急性III-IV级GVHD发生率:MAC组8%(95%CI 3.2-15.6),RIC/NMA组10%(95%CI 4.4-18.4)。
- 1年中/重度慢性GVHD发生率:MAC组10.3%(95%CI 4.4-18.9),RIC/NMA组8.6%(95%CI 3.5-16.6)。
- 供者HLA匹配少于7/8个等位基因的患者(32%)与匹配7/8个等位基因的患者总生存率相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for advanced hematologic malignancies. HSCT using human leukocyte antigen (HLA)-mismatched donors is historically associated with inferior survival. Patients from underrepresented racial and ethnic groups more frequently rely on HLA-mismatched donors. We hypothesized that post-transplant cyclophosphamide (PTCy) based graft versus host disease (GVHD) prophylaxis would improve outcomes for HSCT recipients using peripheral blood stem cells (PBSCs) from HLA-mismatched unrelated donors (MMUDs) by reducing the risk of GVHD. METHODS: This phase II, nonrandomized, multicenter trial assessed PBSCs in the setting of a GVHD prophylaxis regimen of cyclophosphamide, tacrolimus, and mycophenolate mofetil in two adult strata: myeloablative conditioning (MAC) and reduced-intensity or nonmyeloablative (RIC/NMA) conditioning before HSCT from a MMUD. The primary objective was to estimate 1 year overall survival (OS) for each stratum. Key secondary end points included incidences of acute and chronic GVHD. RESULTS: A total of 145 patients enrolled, with 59% self-identifying within an underrepresented group. The 1 year OS was 83.8% (95% CI, 73.1% to 90.4%) for MAC and 78.6% (95% CI, 67% to 86.5%) for RIC/NMA. Incidences of grades III to IV acute GVHD at 6 months were 8% (95% CI, 3.2 to 15.6) for MAC and 10% (95% CI, 4.4 to 18.4) for RIC/NMA. Moderate/severe chronic GVHD at 1 year was 10.3% (95% CI, 4.4 to 18.9) for MAC and 8.6% (95% CI, 3.5 to 16.6) for RIC/NMA. 32% of patients whose donors matched at fewer than seven of eight HLA alleles had similar OS compared with those with donor matched at seven of eight alleles. CONCLUSION: PTCy-based GVHD prophylaxis after MMUD HSCT with PBSC grafts results in favorable 1 year OS. Using MMUDs expands donor availability to all patients regardless of ancestry (ACCESS; ClinicalTrials.gov identifier: NCT04904588).
引用
- Al Malki MM, Bo-Subait S, Logan B, et al. Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation. J Clin Oncol. 2025. PMID: 40523209. doi:10.1200/JCO-25-00856
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。